Obesity-related heart failure with preserved ejection fraction (HFpEF) has become a well-
recognized HFpEF subphenotype. Targeting the unfavorable cardiometabolic profile may …

Background Glucagon‐like peptide 1 (GLP‐1) receptor agonists have been shown to
decrease ethanol (EtOH) drinking in rodent assays. The GLP‐1 system also powerfully …

Cannabis is the most frequently used illicit drug in the United States with more than 45
million users of whom one-third suffer from a cannabis use disorder (CUD). Despite its high …

Ghrelin is a peptide that is produced by endocrine cells that are primarily localized in the
stomach. Ghrelin receptors (GHSR) are expressed in the brain and periphery. Preclinical …

Objective The absorption, distribution and elimination of oral semaglutide, the first oral
glucagon-like peptide-1 receptor agonist for treating type 2 diabetes, was investigated using …

Semaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with a long
elimination half‐life, allowing subcutaneous (sc) administration once per week. Both the …

Aim To investigate the effects of once‐weekly subcutaneous (sc) semaglutide 2.4 mg on
gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A …

The glutamatergic system plays an important role in mediating neurobehavioral effects of
ethanol. Metabotropic glutamate receptors subtype 5 (mGluR5) are modulators of …

Alcoholism is a serious public health concern that is characterized by the development of
tolerance to alcohol's effects, increased consumption, loss of control over drinking and the …

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that
has recently been approved for the treatment of obesity as well. Semaglutide is postulated to …